Why is Labcorp stock sliding today?

Labcorp's stock experienced a sharp decline of 3.4% in after-hours trading, closing at $310. The reason behind this decline was the release of preliminary fee schedule rates by the Centers for Medicare & Medicaid Services (CMS) for Calendar Year 2027. The CMS proposed annual reimbursement cuts of up to 15% starting from January 1, 2027, which they claimed were necessary to correct Medicare's overpayment to laboratories by approximately 16% compared to private insurers.

This move was expected to save around $1 billion per year based on data collected from over 6,400 laboratories. CMS Administrator Dr. Mehmet Oz emphasized that taxpayers and Medicare patients had been paying excessive rates to labs for years, highlighting the political backing behind the cuts. The statutory framework permits reductions of up to 15% annually until 2029, which could have a substantial impact on Labcorp's revenue.

However, at the time of the regular trading session, analysts had not yet revised their earnings per share (EPS) estimates for Labcorp. Despite this, Truist Securities raised its price target on Labcorp to $365 from $350, maintaining a "Buy" rating, demonstrating confidence in the company's long-term fundamentals. The performance of Labcorp's peer, Quest Diagnostics, was similar, as both companies derive a significant portion of their revenue from routine clinical tests billed under the Clinical Laboratory Improvement Amendments (CLIA).

The broader U.S. equity market showed no relief from this decline, with the S&P 500, Dow Jones, and Nasdaq all essentially flat, unchanged, or near their unchanged levels, indicating that the selloff was sector-specific rather than influenced by macroeconomic factors. Taken together, the landmark regulatory repricing of Medicare lab reimbursements, with its multi-year compounding potential and lack of immediate earnings clarity, outweighed the positive signal from Truist's upward price target, causing Labcorp's shares to drop sharply in after-hours trading.

Investors are now facing the challenge of assessing the true revenue exposure ahead of Labcorp's next earnings report, which is expected in late October.